Dr. Giuseppe Badalamenti was born in Mirano (Venice) in 1974. He studied at the University Medical School of Palermo (Italy) and received his MD degree in 1999. He earned the post-graduate specialty in Medical Oncology in 2003. In 2006 he obtained PhD in Clinical, Exprimental Oncology and Tumor Morphology at the University of Palermo. He got a scholarship with the prestigius Dr. Luca Gianni for breast cancer and with Dr. Paolo Casali for rare cancer at the National Cancer Institute of Milan. His research field is rare cancer, in particular soft tissue sarcomas, gastrointestinal stromal tumors and neuroendocrine tumors. Dr. Badalamenti is a active member of the National Rare Cancer Network, Clinical Coordinator of the Sicily Regional Rare Cancer Network, Executive Member of “Italian Sarcoma Group” and author of the Italian guidelines of Soft Tissue Tumors. He is principal investigator in several national and international clinical trials, according to Good Clinical Practice, specifically on rare tumors and he is a member of many tumor board to development new drugs in rare cancer. Dr. Giuseppe Badalamenti was born in Mirano (Venice) in 1974. He studied at the University Medical School of Palermo (Italy) and received his MD degree in 1999. He earned the post-graduate specialty in Medical Oncology in 2003. In 2006 he obtained PhD in Clinical, Exprimental Oncology and Tumor Morphology at the University of Palermo. He got a scholarship with the prestigius Dr. Luca Gianni for breast cancer and with Dr. Paolo Casali for rare cancer at the National Cancer Institute of Milan. His research field is rare cancer, in particular soft tissue sarcomas, gastrointestinal stromal tumors and neuroendocrine tumors. Dr. Badalamenti is a active member of the National Rare Cancer Network, Clinical Coordinator of the Sicily Regional Rare Cancer Network, Executive Member of “Italian Sarcoma Group” and author of the Italian guidelines of Soft Tissue Tumors. He is principal investigator in several national and international clinical trials, according to Good Clinical Practice, specifically on rare tumors and he is a member of many tumor board to development new drugs in rare cancer.

clinical trials in cancer cells